Non Small Cell Lung Cancer: Page 5

Qiagen, NuProbe partner on next-generation sequencing liquid biopsy

By LabPulse.com staff writers

The companies plan to integrate NuProbe's blocker displacement amplification technology with Qiagen's single primer extension technology to analyze DNA mutations with very low variant allele fractions and support noninvasive cancer genomic profiling. They also aim to develop NGS liquid biopsy oncology panels capable of achieving limit-of-detection standards more cost-effectively than other existing technologies.

March 16, 2020

BioMarker Strategies advances immunotherapy test through SBIR grant

By LabPulse.com staff writers

The contract runs for two years and covers use of the test for predicting response to treatments given alone or in combination to patients with non-small cell lung cancer (NSCLC). This represents the second phase of immunotherapy response test development for the NCI; in the first phase, BioMarker Strategies established proof of concept. Immunotherapies have revolutionized the treatment of several cancer types, but there is a strong need for better ways of identifying patients who benefit, as the objective response rates for PD-1/PD-L1 inhibitors are low, ranging from 10% to 30%.

January 6, 2020

FDA clears FoundationOne CDx for Piqray in breast cancer

By LabPulse.com staff writers

Piqray was approved by the FDA in May for second-line treatment in combination with fulvestrant for postmenopausal women and men with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated advanced or metastatic breast cancer.

December 3, 2019

PathAI reports algorithm on par in PD-L1 immunotherapy studies

By LabPulse.com staff writers

The analyses were conducted with Bristol-Myers Squibb (BMS) and tested the algorithm retrospectively in samples from trials of BMS' programmed cell death ligand 1 (PD-L1) inhibitor nivolumab (Opdivo).

November 6, 2019

TRACERx data trove helps refine use of blood markers for lung cancer

By Emily Hayes

The multi-institutional Tracking Non-Small Cell Lung Cancer Evolution Through Therapy (TRACERx) translational research program is studying the genetics of 750 lung cancer patients from the time of diagnosis through surgery and either disease relapse or cure. After surgery, the five-year relapse rate in lung cancer ranges from about 20% in patients with stage I disease to 50% at stage III, the investigators noted.

October 8, 2019

Agilent gets green light in China for PD-L1 companion test

By LabPulse.com staff writers

The assay is approved for use as a companion diagnostic with the checkpoint inhibitor pembrolizumab (Keytruda, Merck) as a monotherapy. Clearance covers use in patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) with expression of the PD-L1 biomarker. Keytruda was just approved for this indication in China, following approval for use in combination with chemotherapy.

October 2, 2019

Thermo Fisher seals companion test deal with Lilly

By LabPulse.com staff writers

LOXO-292 is an investigational drug in phase I/II development for cancers with rearranged during transfection (RET) alterations. An estimated 2% of non-small cell lung cancers and 60% of medullary thyroid cancers have RET alterations.

September 8, 2019

Thermo Fisher flags data for tumor mutation test

By LabPulse.com staff writers

Tumor mutational burden refers to the number of mutations in cancer cells. It has been emerging as a biomarker for response to checkpoint immunotherapies, including drugs targeting programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1), though its role is still not well understood.

September 5, 2019

OncoCyte set to buy Razor, reveals plans for lung cancer tests

By LabPulse.com staff writers

The Razor Genomics molecular prognostic assay is designed to assess risk of recurrence following the resection of early-stage, nonsquamous non-small cell lung cancer. The test received a positive initial coverage decision in August from the U.S. Centers for Medicare and Medicaid Services (CMS), which should pave the way for reimbursement.

September 5, 2019

Bio-Techne's prostate cancer test lands FDA breakthrough status

By LabPulse.com staff writers

With the test, a urine sample is evaluated using real-time quantitative reverse transcription polymerase chain reaction (PCR) technology. A higher EPI score is associated with a greater risk for high-grade prostate cancer on biopsy. The test was launched in 2017 in the U.S. by Exosome Diagnostics, which was acquired by Bio-Techne in 2018.

June 19, 2019

Tumor mutational burden biomarker may not pass muster (again) at ASCO

By Emily Hayes

In one presentation at the meeting, the company will show tumor mutational burden as part of comprehensive genomic profiling was useful for predicting tumor responsiveness to immunotherapy in a study of 3,800 women with three kinds of metastatic breast cancer: HER2-negative (ER-positive/HER2-negative), HER2-amplified, and triple-negative breast cancer. The study outlined the percentage of women with TMB mutations over 10 or 20 mutations per megabase, but it did not correlate genetic status with outcomes.

May 19, 2019

Inivata touts liquid biopsy studies

By LabPulse.com staff writers

The ability of the test of circulating tumor DNA (ctDNA) to detect genetic mutations was evaluated in 264 patients with nonsquamous non-small cell lung cancer (NSCLC) in two multicenter studies. Results were published by Dr. Michael Pritchett and colleagues in the journal on April 25, following their presentation at the World Conference on Lung Cancer in September 2018.

April 25, 2019

Previous Page

Page 5 of 5